<?xml version="1.0" encoding="UTF-8"?>
<p>There are two drugs available in the entry inhibitors class: enfuvirtide—ENF and maraviroc—MCV, with different mechanisms of action, both incorporated into nanoparticles as specified in 
 <xref rid="pharmaceutics-12-00171-t002" ref-type="table">Table 2</xref>. ENF inhibits fusion of the viral and cell membranes mediated by gp41 and CD4 interactions, while MCV is a chemokine receptor antagonist and binds to the host cell CCR5 receptor to block binding of viral gp120. As such, MCV is the only approved antiretroviral drug that targets a host protein [
 <xref rid="B79-pharmaceutics-12-00171" ref-type="bibr">79</xref>,
 <xref rid="B80-pharmaceutics-12-00171" ref-type="bibr">80</xref>,
 <xref rid="B81-pharmaceutics-12-00171" ref-type="bibr">81</xref>].
</p>
